Moderna’s COVID-19 vaccine candidate MRNA-1273 has produced a 94.5% level of efficacy in the first interim analysis of 95 cases from its Phase III COVE trial.
The results have provided more cheer in the fight against the pandemic and are also a boon for the company's...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
